Company research
MAXCYTE, INC.
CIK 1287098Updated Nov 3, 2026
SecurityMXCT · NASDAQ · equity
Historical securities (1)
MAXC · OTC · equity · closed Jul 30, 2021Name history
MAXCYTE INC · through Sep 18, 2008
MXCT price & chart
Loading TradingView…
NASDAQ:MXCT on TradingView ↗About the company
At MaxCyte®, we are committed to building better cells together. As a leading cell engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.
In the news
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
10-Q filing
Entry into a Material Definitive Agreement · Results of Operations and Financial Condition · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 2.02, 3.02, 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 213,476,000Source | 248,612,000Source | 184,672,000Source | 219,750,000Source | 251,496,000Source | 194,473,000Source | 229,961,000Source | 257,930,000Source | 202,507,000Source | 239,470,000Source | 268,274,000Source | 286,653,400Source |
| Property, Plant and Equipment, NetUSD | 18,620,000Source | 20,967,000Source | 14,897,000Source | 19,404,000Source | 21,720,000Source | 16,637,000Source | 19,921,000Source | 22,805,000Source | 17,531,000Source | 19,707,000Source | 23,513,000Source | 23,724,700Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 667,000Source | — | 766,000Source | 638,000Source | — | 783,000Source | 498,000Source | — | 650,000Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 12,973,000Source | 36,958,000Source | 15,042,000Source | 15,225,000Source | 37,513,000Source | 14,557,000Source | 23,385,000Source | 22,249,000Source | 20,065,000Source | 27,884,000Source | 46,506,000Source | 11,064,700Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 8,306,000Source | 4,560,000Source | 3,922,000Source | 5,753,000Source | 4,581,000Source | 4,246,000Source | 5,525,000Source | 5,991,000Source | 3,503,000Source | 4,682,000Source | 5,778,000Source | 11,654,600Source |
| Inventory, NetUSD | 7,611,000Source | 10,393,000Source | 7,798,000Source | 7,933,000Source | 11,159,000Source | 7,631,000Source | 8,274,000Source | 11,960,000Source | 7,547,000Source | 8,914,000Source | 12,229,000Source | 8,580,800Source |
| Assets, CurrentUSD | 124,645,000Source | 172,909,000Source | 121,274,000Source | 143,219,000Source | 175,647,000Source | 122,937,000Source | 155,748,000Source | 178,674,000Source | 118,369,000Source | 171,684,000Source | 190,194,000Source | 252,266,200Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,000,000Source | 4,124,000Source | 3,664,000Source | 2,971,000Source | 2,577,000Source | 4,206,000Source | 3,679,000Source | 3,210,000Source | 4,275,000Source | 3,606,000Source | 3,899,000Source | 2,778,800Source |
| Operating Lease, Right-of-Use AssetUSD | 11,135,000Source | 10,888,000Source | 10,472,000Source | 11,344,000Source | 11,008,000Source | 10,699,000Source | 11,541,000Source | 11,125,000Source | 10,920,000Source | 10,766,000Source | 11,241,000Source | 9,853,500Source |
| Other Assets, NoncurrentUSD | 2,581,000Source | 1,051,000Source | 1,030,000Source | 2,797,000Source | 640,000Source | 2,606,000Source | 1,911,000Source | 295,000Source | 2,467,000Source | 1,532,000Source | 388,000Source | 809,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 33,201,000Source | 35,310,000Source | 25,920,000Source | 29,027,000Source | 30,235,000Source | 26,587,000Source | 30,549,000Source | 31,571,000Source | 31,017,000Source | 33,219,000Source | 36,107,000Source | 32,686,200Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,066,000Source | 1,053,000Source | 1,074,000Source | 1,066,000Source | 1,048,000Source | 1,071,000Source | 1,063,000Source | 1,044,000Source | 1,068,000Source | 1,057,000Source | 1,040,000Source | 1,024,000Source |
| Additional Paid in CapitalUSD | 431,096,000Source | 418,505,000Source | 434,263,000Source | 429,128,000Source | 414,912,000Source | 433,048,000Source | 425,463,000Source | 410,639,000Source | 431,905,000Source | 422,047,000Source | 406,925,000Source | 390,818,500Source |
| Retained Earnings (Accumulated Deficit)USD | -251,887,000Source | -206,256,000Source | -275,107,000Source | -239,471,000Source | -194,699,000Source | -266,233,000Source | -227,114,000Source | -185,324,000Source | -261,483,000Source | -216,853,000Source | -175,798,000Source | -137,875,300Source |
| Stockholders' Equity Attributable to ParentUSD | 180,275,000Source | 213,302,000Source | 158,752,000Source | 190,723,000Source | 221,261,000Source | 167,886,000Source | 199,412,000Source | 226,359,000Source | 171,490,000Source | 206,251,000Source | 232,167,000Source | 253,967,200Source |
| Liabilities and EquityUSD | 213,476,000Source | 248,612,000Source | 184,672,000Source | 219,750,000Source | 251,496,000Source | 194,473,000Source | 229,961,000Source | 257,930,000Source | 202,507,000Source | 239,470,000Source | 268,274,000Source | 286,653,400Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 16,102,000Source | 17,621,000Source | 9,895,000Source | 11,555,000Source | 12,275,000Source | 10,212,000Source | 12,733,000Source | 13,477,000Source | 14,267,000Source | 15,775,000Source | 17,855,000Source | 15,426,500Source |
| Operating Lease, Liability, CurrentUSD | 1,314,000Source | 907,000Source | 1,528,000Source | 1,308,000Source | 878,000Source | 1,374,000Source | 1,276,000Source | 825,000Source | 1,456,000Source | 864,000Source | 774,000Source | 156,800Source |
| Accounts Payable, CurrentUSD | 1,286,000Source | 1,865,000Source | 1,734,000Source | 1,210,000Source | 953,000Source | 1,196,000Source | 2,279,000Source | 1,674,000Source | 1,401,000Source | 1,358,000Source | 743,000Source | 531,800Source |
| Operating Lease, Liability, NoncurrentUSD | 16,847,000Source | 17,412,000Source | 15,723,000Source | 17,199,000Source | 17,650,000Source | 16,113,000Source | 17,546,000Source | 17,815,000Source | 16,487,000Source | 17,170,000Source | 17,969,000Source | 15,938,100Source |
| Other Liabilities, NoncurrentUSD | 227,000Source | 277,000Source | 302,000Source | 248,000Source | 310,000Source | 262,000Source | 270,000Source | 279,000Source | 263,000Source | 274,000Source | 283,000Source | 1,321,600Source |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | 5,196,000Source | 6,653,000Source | 2,463,000Source | 2,640,000Source | 3,368,000Source | 3,271,000Source | 4,145,000Source | 4,476,000Source | 3,598,000Source | 5,251,000Source | 5,069,000Source | 6,712,600Source |
| Short-term InvestmentsUSD | 92,755,000Source | 116,874,000Source | 90,648,000Source | 111,337,000Source | 119,817,000Source | 92,297,000Source | 114,885,000Source | 135,264,000Source | 82,979,000Source | 126,598,000Source | 121,782,000Source | 216,274,900Source |
| Goodwill | —Source | — | — | —Source | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -4,750,000Source | -10,261,000Source | -44,630,000Source | -41,055,000Source | -37,923,000Source | -23,570,800Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 1,047,000Source | 1,096,000Source | 4,340,000Source | 4,315,000Source | 4,171,000Source | 2,697,900Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,141,000Source | 3,039,000Source | 9,213,000Source | 13,083,000Source | 13,979,000Source | 11,752,400Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 743,000Source | 839,000Source | -1,148,000Source | -1,226,000Source | -5,226,000Source | 4,777,600Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 380,000Source | -531,000Source | -575,000Source | -1,362,000Source | 4,534,000Source | 3,493,300Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -8,169,000Source | -14,411,000Source | -34,410,000Source | -27,610,000Source | -21,686,000Source | -14,782,900Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | 1,773,000Source | 1,773,000Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 2,656,000Source | 9,529,000Source | 25,935,000Source | 6,932,000Source | 54,984,000Source | -24,823,300Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 72,000Source | 653,000Source | 1,768,000Source | 1,651,000Source | 3,700,000Source | 18,477,200Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 5,000Source | 383,000Source | 656,000Source | 2,056,000Source | 2,143,000Source | 2,888,500Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -5,508,000Source | -4,499,000Source | -7,819,000Source | -18,622,000Source | 35,441,000Source | -36,717,700Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 12,973,000Source | 36,958,000Source | 15,042,000Source | 15,225,000Source | 14,557,000Source | 23,385,000Source | 20,065,000Source | 27,884,000Source | 46,506,000Source | 11,064,700Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,954,000Source | 3,370,000Source | 1,160,000Source | 3,514,000Source | 1,141,000Source | 3,039,000Source | 9,213,000Source | 13,083,000Source | 13,979,000Source | 11,752,400Source |
| Amortization of Intangible AssetsUSD | — | — | 15,000Source | — | 17,000Source | 12,000Source | 17,000Source | 10,000Source | 53,000Source | — | — | — |
| Deferred Other Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 11,812,000Source | 9,228,000Source | 12,294,000Source | 3,240,500Source |
| DepreciationUSD | — | — | 1,057,000Source | 1,066,000Source | 961,000Source | 1,089,000Source | 1,030,000Source | 1,086,000Source | 4,287,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -11,000Source | -2,000Source | -67,000Source | 26,000Source | -84,000Source | -19,000Source | -70,000Source | -140,000Source | -84Source | -79,100Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | -47,000Source | -287,000Source | -861,000Source | -30,000Source | -139,500Source |
| General and Administrative ExpenseUSD | — | — | 6,028,000Source | 7,745,000Source | 7,258,000Source | 8,080,000Source | 5,966,000Source | 8,526,000Source | 28,116,000Source | 29,693,000Source | 30,068,000Source | 25,828,700Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 3,554,000Source | — | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | 197,000Source | 65,000Source | 676,000Source | 1,771,000Source | 697,000Source | — |
| Investment Income, InterestUSD | — | — | 1,733,000Source | 2,496,000Source | 1,358,000Source | 1,870,000Source | 1,435,000Source | 2,034,000Source | 7,267,000Source | 10,142,000Source | 10,376,000Source | 3,916,600Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,416,000Source | -11,557,000Source | -8,874,000Source | -12,357,000Source | -4,750,000Source | -10,261,000Source | -44,630,000Source | -41,055,000Source | -37,923,000Source | -23,570,800Source |
| Operating ExpensesUSD | — | — | 19,382,000Source | 20,289,000Source | 15,828,000Source | 21,215,000Source | 14,267,000Source | 21,188,000Source | 78,701,000Source | 82,724,000Source | 84,845,000Source | 66,523,600Source |
| Operating Lease, Lease IncomeUSD | — | — | 2,226,000Source | 2,552,000Source | 2,335,000Source | 2,683,000Source | 5,150,000Source | 4,647,000Source | 12,069,000Source | 16,412,000Source | 21,791,000Source | 15,512,600Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,733,000Source | 2,496,000Source | 1,358,000Source | 1,870,000Source | 1,435,000Source | 2,034,000Source | 7,267,000Source | 10,142,000Source | 10,376,000Source | 3,789,700Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 25,122,000Source | 34,645,000Source | 126,286,000Source | 150,857,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 5,000Source | 383,000Source | 432,000Source | 1,597,000Source | 1,874,000Source | 2,888,500Source |
| Goodwill | — | — | —Source | — | — | —Source | — | —Source | — | — | — | — |
| Goodwill and Intangible Asset Impairment | — | — | — | — | — | —Source | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 4,603,000Source | 5,612,000Source | 4,936,000Source | 5,824,000Source | 9,651,000Source | 5,743,000Source | 20,957,000Source | 22,215,000Source | 41,288,000Source | 28,748,900Source |
| Cost of RevenueUSD | — | — | 1,596,000Source | 1,928,000Source | 1,675,000Source | 1,519,000Source | 1,569,000Source | 1,497,000Source | 6,222,000Source | 7,100,000Source | 4,742,000Source | 5,098,400Source |
| Operating Income (Loss)USD | — | — | -14,149,000Source | -14,053,000Source | -10,232,000Source | -14,227,000Source | -6,185,000Source | -12,295,000Source | -51,897,000Source | -51,197,000Source | -48,299,000Source | -27,360,500Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,733,000Source | 2,496,000Source | 1,358,000Source | 1,870,000Source | 1,435,000Source | 2,034,000Source | 7,267,000Source | 10,142,000Source | 10,376,000Source | 3,789,700Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -12,416,000Source | -11,557,000Source | -8,874,000Source | -12,357,000Source | -4,750,000Source | -10,261,000Source | -44,630,000Source | -41,055,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,416,000Source | -11,557,000Source | -8,874,000Source | -12,357,000Source | -4,750,000Source | -10,261,000Source | -44,630,000Source | -41,055,000Source | -37,923,000Source | -23,570,800Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.12Source | -0.11Source | -0.08Source | -0.12Source | -0.04Source | -0.1Source | -0.42Source | -0.39Source | -0.37Source | -0.23Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.12Source | -0.11Source | -0.08Source | -0.12Source | -0.04Source | -0.1Source | -0.42Source | -0.39Source | -0.37Source | -0.23Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 106,613,075Source | 105,109,603Source | 106,822,633Source | 106,403,540Source | 106,875,087Source | 105,950,480Source | 106,427,854Source | 104,849,222Source | 103,268,502Source | 101,702,664Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 106,613,075Source | 105,109,603Source | 106,822,633Source | 106,403,540Source | 106,875,087Source | 105,950,480Source | 106,427,854Source | 104,849,222Source | 103,268,502Source | 101,702,664Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 15,000Source | — | 17,000Source | 12,000Source | 17,000Source | 10,000Source | 53,000Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 1,044,000Source | 1,021,000Source | 953,000Source | 1,080,000Source | 1,016,000Source | 1,061,000Source | 4,226,000Source | 4,143,000Source | 3,985,000Source | 2,527,600Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -11,000Source | -2,000Source | -67,000Source | 26,000Source | -84,000Source | -19,000Source | -70,000Source | -140,000Source | -84Source | -79,100Source |
| General and Administrative ExpenseUSD | — | — | 6,028,000Source | 7,745,000Source | 7,258,000Source | 8,080,000Source | 5,966,000Source | 8,526,000Source | 28,116,000Source | 29,693,000Source | 30,068,000Source | 25,828,700Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 3,554,000Source | — | — | — |
| Gross ProfitUSD | — | — | 5,233,000Source | 6,236,000Source | 5,596,000Source | 6,988,000Source | 8,082,000Source | 8,893,000Source | 26,804,000Source | 31,527,000Source | 36,546,000Source | 39,163,100Source |
| Investment Income, InterestUSD | — | — | 1,733,000Source | 2,496,000Source | 1,358,000Source | 1,870,000Source | 1,435,000Source | 2,034,000Source | 7,267,000Source | 10,142,000Source | 10,376,000Source | 3,916,600Source |
| Operating ExpensesUSD | — | — | 19,382,000Source | 20,289,000Source | 15,828,000Source | 21,215,000Source | 14,267,000Source | 21,188,000Source | 78,701,000Source | 82,724,000Source | 84,845,000Source | 66,523,600Source |
| Operating Lease, Lease IncomeUSD | — | — | 2,226,000Source | 2,552,000Source | 2,335,000Source | 2,683,000Source | 5,150,000Source | 4,647,000Source | 12,069,000Source | 16,412,000Source | 21,791,000Source | 15,512,600Source |
| Research and Development ExpenseUSD | — | — | 5,316,000Source | 5,316,000Source | 4,253,000Source | 6,269,000Source | 3,857,000Source | 5,903,000Source | 20,823,000Source | 22,227,000Source | 23,817,000Source | 19,514,400Source |
| Selling and Marketing ExpenseUSD | — | — | 3,936,000Source | 6,207,000Source | 3,364,000Source | 5,786,000Source | 3,428,000Source | 5,698,000Source | 18,924,000Source | 26,661,000Source | 26,975,000Source | 18,652,900Source |
Filing attachments
tm2629420d1_ex99-1.htm · 8-K · 2026-11-10
Exhibit 99.1 MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance MaxCyte will host its third quarter 2026 earnings call today, November 10th, at 8:30 a.m. Eastern Time Third Quarter and Recent Business Highlights: Reports total revenue of $10.2 million for the third quarter of 2026, including $8.2 million of core revenue and $2.0 million of SPL Program-related revenue Raises Full Year 2026 Total Revenue Guidance to at least $34.5 …
Read attachment ↗tm2629420d1_ex99-2.htm · 8-K · 2026-11-10
Exhibit 99.2 MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base Akron Bio is a leading supplier of GMP-grade reagents and ancillary materials Expands MaxCyte’s footprint across the cell therapy manufacturing workflow and establishes a combined portfolio supporting five commercially approved therapies Akron Bio is expected to generate approximately $28 million in revenue and $7-8 million in EBITDA in 2026…
Read attachment ↗tm2627568d1_ex99-1.htm · 8-K · 2026-10-14
Exhibit 99.1 MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 ROCKVILLE, MD, October 14, 2026 - MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter e…
Read attachment ↗mxct-20260812xex99d1.htm · 8-K · 2026-08-12
EX-99.1 2 mxct-20260812xex99d1.htm EX-99.1 Exhibit 99.1 MaxCyte Reports Second Quarter 2026 Financial Results Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately $5.5 million of common stock to date under the Company’s $10 million share repurchase program authorized by the Board Following end of quarter, announced s…
Read attachment ↗mxct-20260812xex99d2.htm · 8-K · 2026-08-12
EX-99.2 3 mxct-20260812xex99d2.htm EX-99.2 Exhibit 99.2 are trademarks of MaxCyte, Inc. in the U.S.A. Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT August 2026 © 2026 MaxCyte, Inc. All Rights Reserved ───────────────────────────────────────────────── Forward Looking Statement Disclaimer 2 © 2026 MaxCyte, Inc. All Rights Reserved Certain statements in this document (this “Presentation”) are, or may be deemed to be, forwa…
Read attachment ↗mxct-20260512xex99d1.htm · 8-K · 2026-05-12
EX-99.1 2 mxct-20260512xex99d1.htm EX-99.1 Exhibit 99.1 MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million MaxCyte’s Board authorized a $10 million share repur…
Read attachment ↗